An Audience With

Filter By:

Article Type
Year

  • Ida Sim, Vivli co-founder and UCSF informatician, discusses the need for a neutral broker platform that can facilitate access to and analysis of industry and academic patient-level clinical trial data.

    An Audience With

  • Penny Heaton, CEO of the Bill and Melinda Gates Medical Research Institute, discusses how the recently launched non-profit biotech will tackle the translational science of TB, malaria and diarrhoeal diseases.

    An Audience With

  • Saurabh Saha, head of Translational Medicine at Bristol-Myers Squibb, discusses how new tools are opening up translational opportunities in immuno-oncology

    An Audience With

  • Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.

    An Audience With

  • Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.

    An Audience With

  • Anja König, Global Head of the Novartis Venture Fund, discusses the changing corporate venture capital landscape.

    An Audience With

  • George Yancopoulos, CSO of Regeneron, discusses his 30 years at Regeneron, the company's evolving growth plans and the recent launch of a precompetitive collaboration to sequence 500,000 UK Biobank exomes.

    An Audience With

  • Fiona Marshall — co-founder of Heptares, former chief scientific officer of Sosei and soon to be lead of Merck & Co.'s new research facility in London — looks back on 30 years of GPCRs, and looks forward to the emerging therapeutic opportunities these targets still offer.

    An Audience With

  • Morgan Sheng, Vice President of Neuroscience at Genentech, discusses his continued faith in the amyloid hypothesis, the promise of the genetics of neurodegenerative disorders and the overlap between psychiatric disease and neurodegeneration.

    An Audience With

  • Sean Harper, Amgen's Chief Scientific Officer, talks about how human genetic data can be used to avoid costly failures, prosecute programmes more effectively and discoverde novodrug targets.

    An Audience With

  • Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.

    An Audience With

  • Nora Volkow, director of the National Institute on Drug Abuse (NIDA), discusses her ambitious aim of halving the time needed to develop non-opioid analgesics and anti-addiction drugs.

    An Audience With

  • Katrine Bosley, CEO of Editas Medicines, discusses the technological tractability of CRISPR, the future of the modality's pipeline and the ethical responsibility of working in this space.

    An Audience With

  • Nigel Blackburn, Director of drug development at CRUK, discusses the charity's changing approach to bolstering the cancer drug pipeline.

    An Audience With

  • Joshua Gordon, Director of the National Institute of Mental Health, discusses the evolving RDoC framework for research into mental illnesses, and the appropriate balance between the funding of basic and clinical research.

    An Audience With

  • Yong-Jun Liu, head of research at Sanofi, discusses his push to refocus the company on internal early-stage drug discovery.

    An Audience With

  • Birgitte Volck, head of rare disease R&D at GlaxoSmithKline, discusses the new era of rare disease drug discovery and development.

    An Audience With

  • Thomas Lynch, Bristol-Myers Squibb's new Chief Scientific Officer, discusses his R&D priorities, genomics diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.

    An Audience With

  • Jay Bradner, President of the Novartis Institutes for BioMedical Research, discusses increased interest in chemical biology and open science at Novartis.

    An Audience With

  • Melinda Richter, head of JLABS at J&J Innovation, celebrates the fifth anniversary of a big pharma experiment with life science incubators.

    An Audience With